Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017

Disclosures: Disclosures to report. NSR has been member of the Vetoryl novel monitoring meeting 2017 organized by Dechra Veterinary Products Ltd. CR was consultant for Boehringer Ingelheim and Novartis Animal Health and is currently consultant for Dechra Limited. She has received financial support for her endocrine research from various companies such as Nestl e Purina, Hills, Provet, Antlia SA, Glycemicon and from the clinical studies fund of the ECVIM-CA and from the Society of Comparative Endocrinology. Current medical treatment options in dogs with cortisol-secreting adrenocortical tumors (ATs) are trilostane or mitotane. However, trilostane is a palliative treatment and has no effect on the tumor itself, while mitotane does have adrenocorticolytic activity, but can cause serious adverse effects. ATR-101, a new orally available drug, is known to have selective adrenocorticolytic activity in guinea pigs, dogs, monkeys and humans, and is currently being tested in a phase II clinical trial for ATs in humans. ATR-101 is a selective and potent sterol-O-acyltransferase 1 (SOAT1) inhibitor, which leads to the accumulation of free cholesterol in adrenocortical cells, resulting in endoplasmic reticulum stress and ultimately leading to apoptosis. Inhibition of SOAT1 could be an interesting therapy option in dogs with ATs, but can only be useful if canine ATs express SOAT1.